11/5/2009

The CMS approved reimbursement for Spectrum Pharmaceuticals' non-Hodgkin's lymphoma drug Zevalin, effective Jan. 1. The ruling removes "a significant historical barrier" to use of the drug, CEO Rajesh Shrotriya said.

Full Story:
Reuters

Related Summaries